You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to November 2024

AbstractFullPdf
Nov 2020267035
Dec 20202507
Jan 20213606
Feb 20212804
Mar 2021122027
Apr 20215008
May 20212607
Jun 20210016
Jul 20210013
Aug 20210019
Sep 20210016
Oct 202188032
Nov 2021112031
Dec 2021102010
Jan 2022112015
Feb 2022106017
Mar 2022186030
Apr 2022116024
May 2022114021
Jun 2022138021
Jul 2022198016
Aug 2022174011
Sep 202294010
Oct 2022136016
Nov 2022142020
Dec 202296012
Jan 20237207
Feb 202390010
Mar 2023192019
Apr 2023102012
May 2023110012
Jun 2023122021
Jul 202394016
Aug 2023104011
Sep 202362011
Oct 202386017
Nov 20238606
Dec 20236807
Jan 20243802
Feb 20245003
Mar 20243805
Apr 20244605
May 20246404
Jun 20244807
Jul 20245608
Aug 20246804
Sep 20244606
Oct 202430016
Nov 20244608
Total41860661